Evaluation of a 64Cu-labeled 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA)-galactose-bombesin analogue as a PET imaging probe in a gastrin-releasing peptide receptor-expressing prostate cancer xenograft model

Min Hwan Kim, Ji Ae Park, Sang Keun Woo, Kyo Chul Lee, Gwang Il An, Byoung Soo Kim, Kwang Il Kim, Tae Sup Lee, Chan Wha Kim, Kyeong Min Kim, Joo Hyun Kang, Yong Jin Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Gastrin-releasing peptide receptor (GRPR) is overexpressed by a variety of human tumors and in particular, identified to be upregulated in prostate cancers. The current study aimed to develop clinically translatable BBN analogue-based radioligands for positron emission tomography (PET) of GRPR-positive tumors. We developed radiolabeled BBN analogues and modified radiolabeled galacto-BBN analogues and then investigated their tumor-targeting efficacy in vivo. The chelator 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA) was used to radiolabel the peptides with 64Cu. The peptides were evaluated by measuring cell-based receptor-binding affinities. Biodistribution experiments and small animal imaging using PET were performed in nude mice bearing subcutaneous PC3 human prostate cancer xenografts. The conjugates were radiolabeled with yields >99%. The stability assay showed that [64Cu]NODAGA-BBN and [64Cu]NODAGA-galacto-BBN remained stable in both human and mouse serum for 1 h at 37°C. PET images of PC3 tumor-bearing nude mice were acquired at 1, 3, 24, 48 and 72 h after injection. [64Cu]NODAGA-galacto-BBN showed retention in tumors for 72 h, low liver uptake, and rapid renal clearance. PET imaging results were also confirmed by biodistrubution 1 and 3 h after injection. [64Cu]NODAGA-BBN and [64Cu]NODAGA-galacto-BBN are promising new PET probes for GRPR-positive prostate cancer.

Original languageEnglish
Pages (from-to)1159-1168
Number of pages10
JournalInternational Journal of Oncology
Volume46
Issue number3
DOIs
Publication statusPublished - 2015 Mar 1

Fingerprint

Bombesin Receptors
Bombesin
Galactose
Heterografts
Positron-Emission Tomography
Prostatic Neoplasms
Neoplasms
Nude Mice
Peptides
Injections
Chelating Agents
1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane
Kidney
Liver

Keywords

  • Cu
  • Bombesin
  • Positron emission tomography
  • Prostate cancer
  • Radiopharmaceuticals

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluation of a 64Cu-labeled 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA)-galactose-bombesin analogue as a PET imaging probe in a gastrin-releasing peptide receptor-expressing prostate cancer xenograft model. / Kim, Min Hwan; Park, Ji Ae; Woo, Sang Keun; Lee, Kyo Chul; An, Gwang Il; Kim, Byoung Soo; Kim, Kwang Il; Lee, Tae Sup; Kim, Chan Wha; Kim, Kyeong Min; Kang, Joo Hyun; Lee, Yong Jin.

In: International Journal of Oncology, Vol. 46, No. 3, 01.03.2015, p. 1159-1168.

Research output: Contribution to journalArticle

Kim, Min Hwan ; Park, Ji Ae ; Woo, Sang Keun ; Lee, Kyo Chul ; An, Gwang Il ; Kim, Byoung Soo ; Kim, Kwang Il ; Lee, Tae Sup ; Kim, Chan Wha ; Kim, Kyeong Min ; Kang, Joo Hyun ; Lee, Yong Jin. / Evaluation of a 64Cu-labeled 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA)-galactose-bombesin analogue as a PET imaging probe in a gastrin-releasing peptide receptor-expressing prostate cancer xenograft model. In: International Journal of Oncology. 2015 ; Vol. 46, No. 3. pp. 1159-1168.
@article{c5c0961850984f51b8aea883fb7ab740,
title = "Evaluation of a 64Cu-labeled 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA)-galactose-bombesin analogue as a PET imaging probe in a gastrin-releasing peptide receptor-expressing prostate cancer xenograft model",
abstract = "Gastrin-releasing peptide receptor (GRPR) is overexpressed by a variety of human tumors and in particular, identified to be upregulated in prostate cancers. The current study aimed to develop clinically translatable BBN analogue-based radioligands for positron emission tomography (PET) of GRPR-positive tumors. We developed radiolabeled BBN analogues and modified radiolabeled galacto-BBN analogues and then investigated their tumor-targeting efficacy in vivo. The chelator 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA) was used to radiolabel the peptides with 64Cu. The peptides were evaluated by measuring cell-based receptor-binding affinities. Biodistribution experiments and small animal imaging using PET were performed in nude mice bearing subcutaneous PC3 human prostate cancer xenografts. The conjugates were radiolabeled with yields >99{\%}. The stability assay showed that [64Cu]NODAGA-BBN and [64Cu]NODAGA-galacto-BBN remained stable in both human and mouse serum for 1 h at 37°C. PET images of PC3 tumor-bearing nude mice were acquired at 1, 3, 24, 48 and 72 h after injection. [64Cu]NODAGA-galacto-BBN showed retention in tumors for 72 h, low liver uptake, and rapid renal clearance. PET imaging results were also confirmed by biodistrubution 1 and 3 h after injection. [64Cu]NODAGA-BBN and [64Cu]NODAGA-galacto-BBN are promising new PET probes for GRPR-positive prostate cancer.",
keywords = "Cu, Bombesin, Positron emission tomography, Prostate cancer, Radiopharmaceuticals",
author = "Kim, {Min Hwan} and Park, {Ji Ae} and Woo, {Sang Keun} and Lee, {Kyo Chul} and An, {Gwang Il} and Kim, {Byoung Soo} and Kim, {Kwang Il} and Lee, {Tae Sup} and Kim, {Chan Wha} and Kim, {Kyeong Min} and Kang, {Joo Hyun} and Lee, {Yong Jin}",
year = "2015",
month = "3",
day = "1",
doi = "10.3892/ijo.2015.2832",
language = "English",
volume = "46",
pages = "1159--1168",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Evaluation of a 64Cu-labeled 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA)-galactose-bombesin analogue as a PET imaging probe in a gastrin-releasing peptide receptor-expressing prostate cancer xenograft model

AU - Kim, Min Hwan

AU - Park, Ji Ae

AU - Woo, Sang Keun

AU - Lee, Kyo Chul

AU - An, Gwang Il

AU - Kim, Byoung Soo

AU - Kim, Kwang Il

AU - Lee, Tae Sup

AU - Kim, Chan Wha

AU - Kim, Kyeong Min

AU - Kang, Joo Hyun

AU - Lee, Yong Jin

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Gastrin-releasing peptide receptor (GRPR) is overexpressed by a variety of human tumors and in particular, identified to be upregulated in prostate cancers. The current study aimed to develop clinically translatable BBN analogue-based radioligands for positron emission tomography (PET) of GRPR-positive tumors. We developed radiolabeled BBN analogues and modified radiolabeled galacto-BBN analogues and then investigated their tumor-targeting efficacy in vivo. The chelator 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA) was used to radiolabel the peptides with 64Cu. The peptides were evaluated by measuring cell-based receptor-binding affinities. Biodistribution experiments and small animal imaging using PET were performed in nude mice bearing subcutaneous PC3 human prostate cancer xenografts. The conjugates were radiolabeled with yields >99%. The stability assay showed that [64Cu]NODAGA-BBN and [64Cu]NODAGA-galacto-BBN remained stable in both human and mouse serum for 1 h at 37°C. PET images of PC3 tumor-bearing nude mice were acquired at 1, 3, 24, 48 and 72 h after injection. [64Cu]NODAGA-galacto-BBN showed retention in tumors for 72 h, low liver uptake, and rapid renal clearance. PET imaging results were also confirmed by biodistrubution 1 and 3 h after injection. [64Cu]NODAGA-BBN and [64Cu]NODAGA-galacto-BBN are promising new PET probes for GRPR-positive prostate cancer.

AB - Gastrin-releasing peptide receptor (GRPR) is overexpressed by a variety of human tumors and in particular, identified to be upregulated in prostate cancers. The current study aimed to develop clinically translatable BBN analogue-based radioligands for positron emission tomography (PET) of GRPR-positive tumors. We developed radiolabeled BBN analogues and modified radiolabeled galacto-BBN analogues and then investigated their tumor-targeting efficacy in vivo. The chelator 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA) was used to radiolabel the peptides with 64Cu. The peptides were evaluated by measuring cell-based receptor-binding affinities. Biodistribution experiments and small animal imaging using PET were performed in nude mice bearing subcutaneous PC3 human prostate cancer xenografts. The conjugates were radiolabeled with yields >99%. The stability assay showed that [64Cu]NODAGA-BBN and [64Cu]NODAGA-galacto-BBN remained stable in both human and mouse serum for 1 h at 37°C. PET images of PC3 tumor-bearing nude mice were acquired at 1, 3, 24, 48 and 72 h after injection. [64Cu]NODAGA-galacto-BBN showed retention in tumors for 72 h, low liver uptake, and rapid renal clearance. PET imaging results were also confirmed by biodistrubution 1 and 3 h after injection. [64Cu]NODAGA-BBN and [64Cu]NODAGA-galacto-BBN are promising new PET probes for GRPR-positive prostate cancer.

KW - Cu

KW - Bombesin

KW - Positron emission tomography

KW - Prostate cancer

KW - Radiopharmaceuticals

UR - http://www.scopus.com/inward/record.url?scp=84921926434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921926434&partnerID=8YFLogxK

U2 - 10.3892/ijo.2015.2832

DO - 10.3892/ijo.2015.2832

M3 - Article

C2 - 25586565

AN - SCOPUS:84921926434

VL - 46

SP - 1159

EP - 1168

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -